Health news
Health news top Health news

   Login  |  Register    
Health News Make AMN Your Home PageDiscussion BoardsAdvanced Search ToolMedical RSS/XML News FeedHealth news
  You are here : Health.am > Health Centers > Drug News -
Pfizer Stomach-Cancer Drug Succeeds in Trial Pfizer Stomach-Cancer Drug Succeeds in Trial

Pfizer Stomach-Cancer Drug Succeeds in Trial

Drug NewsFeb 08, 2005

Pfizer Inc. on Tuesday said its experimental drug for a deadly form of stomach cancer proved safe and effective in a late-stage trial, prompting researchers to halt the study seven months ahead of schedule.

The world’s largest drugmaker said patients who had been receiving a dummy medicine in the trial now have the option of switching to the Pfizer drug, SU11248, given its strong showing in the Phase III study.

The medicine is being developed to treat patients with gastrointestinal stromal tumors, or GIST, who have failed to benefit from Novartis AG’s Gleevec therapy. The cancer is diagnosed each year in 5,000 to 10,000 Americans.

The Pfizer drug inhibits several kinases, a type of enzyme involved in tumor growth.

The New York-based drugmaker acquired SU11248 through its 2003 merger with rival U.S. drugmaker Pharmacia. The drug is also being studied as a treatment for kidney cancer.

Last June, researchers created excitement at a medical meeting with data showing SU11248 shrank kidney and stomach tumors or impressively prevented new tumor growth in two different early-stage trials.

All stomach cancer patients in one of the earlier trials had previously taken Gleevec, which is approved for GIST, but none were benefiting from it any longer. Researchers said more than half the patients getting the once-daily Pfizer pill saw either shrinkage of tumors or no worsening of their condition for six months or more.

In the other small earlier trial, involving patients with kidney cancer who failed to benefit from other treatments, tumors shrank in 33 percent of the patients. Researchers said that was a sixfold improvement compared with typical results seen with the best standard treatments.

Pfizer shares were up 42 cents, or 1.7 percent, to $25.33 in morning trade on the New York Stock Exchange.

Provided by ArmMed Media
Revision date: July 5, 2011
Last revised: by Dave R. Roger, M.D.

Pfizer Stomach-Cancer Drug Succeeds in Trial Bookmark this! Pfizer Stomach-Cancer Drug Succeeds in Trial

RELATED STORIES:


 Comments [ + Post Your Own

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]




We are pleased to let readers post comments about an article. Please increase the credibility of your post by including your full name and email.

All comments are reviewed by our editors before they are posted on the site. Just keep it clean, kids.

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

Please enter the word you see in the image below:


   [advanced search]   
What health info have you recently searched for online?
Disease or condition
Exercise or fitness
Diet, nutrition or vitamins
None of the above


Get free support - Headache Causes, Symptoms, Diagnosis, and Treatment on HeadacheCare.net


Health Centers







Diabetes

















Health news
  


Health Encyclopedia

Diseases & Conditions

Drugs & Medications

Health Tools

Health Tools



   Health newsletter

  





   Medical Links



   RSS/XML News Feed



   Feedback


Add to Yahoo RSS News Feed



Google Reader




Syndicate


This website is accredited by Health On the Net Foundation. Click to verify. We comply with the HONcode standard for trustworthy health information:
Verify here.




Urology Problems and Information: Doctor-Reviewed Articles at UrologyToday.net